Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMI anticoagulation strategy trial
ACTRN12610000152022Phase 4Terminated
- Sponsor
- Professor John French
- Start
- Aug 2010
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bivalirudin, heparin, abciximab, eptifibatide and tirofiban in myocardial infarction (MI) (2 arms), sponsored by Professor John French. Primary endpoint: ACUITY major and minor bleeding. Started Aug 2010; status: terminated.
02
Drugs
bivalirudinheparinabciximabeptifibatidetirofiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ACTRN12610000152022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000152022.